 for people to be taking GLP-1 drugs chronically over a very long period of time. We don't really have data yet. So I think that investors are right to be nervous. I feel like this is pretty much overblown, given the evidence that we have. All right. Coming up after the break, we've got a down outlook on two huge brands in retail. Stay right here. You're listening to Motley Fool Money.